| The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? |
| |
| 作者姓名： | Acton SL Kozarsky KF Rigotti A |
| |
| 摘 要： |
|
The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? |
| |
| Acton SL,Kozarsky KF,Rigotti A.The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?[J].Molecular medicine today,1999,5(12):518-524. |
| |
| Authors: | Acton S L Kozarsky K F Rigotti A |
| |
| Institution: | Cardiovascular Biology, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA. |
| |
| Abstract: | Although high-density lipoprotein (HDL) metabolism is a crucial process for cholesterol homeostasis and coronary heart disease, therapeutic approaches for selective modification of plasma HDL levels are not currently available. The discovery of well-defined cell-surface HDL receptors should provide new avenues for treatment of atherosclerotic cardiovascular disease. In fact, SR-BI, a recently identified receptor for selective HDL cholesterol uptake, is relevant for physiological processes (for example, HDL metabolism, steroidogenesis and biliary cholesterol secretion) and pathophysiological conditions (for example, atherosclerosis) in animal models. If SR-BI has similar activities in humans, it might represent a new therapeutic target for atherosclerosis. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
